Log In
Print
BCIQ
Print
Print this Print this
 

oral plasma kallikrein inhibitors

  Manage Alerts
Collapse Summary General Information
Company KalVista Pharmaceuticals Ltd.
DescriptionOral plasma kallikrein inhibitors
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetic macular edema (DME)
Indication DetailsTreat diabetic macular edema (DME)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today